Values First Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Values First Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-556	Closed	-$60.7K	–	369
2023 Q1	$60.7K	Buy	+556	New	+$61.5K	0.04%	181

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Values First Advisors's HZNP Position: Q2 2023 in Review

Values First Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 556 shares — an estimated $60.7K sold.

Values First Advisors first reported a position in HZNP in Q1 2023 and held it in 1 quarter. The position peaked at $60.7K in Q1 2023. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Values First Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Values First Advisors sold 556 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $60.7K.
Values First Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 1 quarter.
Values First Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $60.7K in Q1 2023.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.